Payment overview · 2025
General Payments
$46.36
2 reported records · 2 companies
Healthcare provider profile · identity verified
Steven U Wolf, DO
Allopathic & Osteopathic Physicians|Internal Medicine · PHILADELPHIA, PA · NPI 1861402828
Verified facts
What the public records show
CMS Open Payments records show Steven U Wolf, DO received $46.36 in general payments during 2025 across 2 reported records.
SANOFI PASTEUR INC. accounted for 61.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $28.50 | 61.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.86 | 38.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $46.36 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 755 | 197 |
| Amlodipine Besylate | Amlodipine Besylate | 557 | 137 |
| Lisinopril | Lisinopril | 350 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 317 | 80 |
| Metformin Hcl | Metformin Hcl | 268 | 66 |
| Omeprazole | Omeprazole | 244 | 62 |
| Losartan Potassium | Losartan Potassium | 236 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 180 | 45 |
| Gabapentin | Gabapentin | 177 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 169 | 50 |
| Simvastatin | Simvastatin | 152 | 42 |
| Furosemide | Furosemide | 139 | 40 |
| Eliquis | Apixaban | 125 | 25 |
| Sertraline Hcl | Sertraline Hcl | 122 | 31 |
| Valsartan | Valsartan | 122 | 30 |
| Lorazepam | Lorazepam | 121 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 117 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 29 |
| Tramadol Hcl | Tramadol Hcl | 113 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 25 |
| Alprazolam | Alprazolam | 99 | 20 |
| Glipizide Er | Glipizide | 87 | 21 |
| Carvedilol | Carvedilol | 83 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 78 | 16 |
| Allopurinol | Allopurinol | 76 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 14 |
| Lovastatin | Lovastatin | 70 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 19 |
| Famotidine | Famotidine | 69 | 22 |
| Montelukast Sodium | Montelukast Sodium | 65 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 20 |
| Alendronate Sodium | Alendronate Sodium | 59 | 18 |
| Atenolol | Atenolol | 56 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 13 |
| Metformin Hcl Er | Metformin Hcl | 54 | 15 |
| Meloxicam | Meloxicam | 53 | 13 |
| Trazodone Hcl | Trazodone Hcl | 53 | 11 |
| Xarelto | Rivaroxaban | 53 | 11 |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Clonazepam | Clonazepam | 48 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | suppressed |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Prednisone | Prednisone | 46 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 11 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 12 |
| Glipizide | Glipizide | 41 | 12 |
| Ozempic | Semaglutide | 41 | suppressed |
| Diazepam | Diazepam | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 11 |
| Glimepiride | Glimepiride | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Repaglinide | Repaglinide | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 21 |
| Spironolactone | Spironolactone | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 20 | suppressed |
| Felodipine Er | Felodipine | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 13 |
| Nystatin | Nystatin | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Veo Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $46.36 · 2 records | SANOFI PASTEUR INC. | AREXVY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, SHINGRIX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error